^
    18h
    FOCUS: Fluorescence-Guided Optimization of Sarcoma Margins (clinicaltrials.gov)
    P=N/A, N=90, Recruiting, University of Aarhus | Not yet recruiting --> Recruiting
    Enrollment open
    2d
    Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Novartis Pharmaceuticals
    New P1 trial
    2d
    Alveolar Soft Part Sarcoma in a 44-year-Old Female: A Case from Uganda. (PubMed, Int Med Case Rep J)
    This case highlights the occurrence of ASPS in an older-than-typical patient and underscores the enduring reliability of classic histopathology for definitive diagnosis in resource-limited settings like Uganda. Although surgically cured locally, the patient's large tumor size and age confer a high risk for future metastasis, mandating rigorous, long-term surveillance.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4)
    2d
    ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival. (PubMed, medRxiv)
    ATRX status may serve as a potential biomarker for prognosis and therapeutic stratification. Future clinical trials investigating epigenetic therapies could offer novel treatment strategies for ATRX-deficient sarcomas.
    Journal
    |
    ATRX (ATRX Chromatin Remodeler)
    3d
    PRALISS: Preventive Application of Single-use Negative Pressure Wound Therapy (sNPWT) in the Postoperative Course of Radiotreatated Limb Sarcoma Surgery (clinicaltrials.gov)
    P=N/A, N=48, Recruiting, Istituto Oncologico Veneto IRCCS | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    ONITT: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (clinicaltrials.gov)
    P1/2, N=90, Recruiting, St. Jude Children's Research Hospital | Active, not recruiting --> Recruiting | N=46 --> 90
    Enrollment open • Enrollment change
    |
    EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)
    4d
    BOLDSARC-01: BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, University Health Network, Toronto | Initiation date: Jun 2025 --> Mar 2026
    Trial initiation date
    |
    doxorubicin hydrochloride • BOLD-100
    4d
    PROTraSarc: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients (clinicaltrials.gov)
    P=N/A, N=7, Terminated, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed --> Terminated; The study was terminated prematurely due to slow recruitment after inclusion of 7 patients (of initially planned 100 patients).
    Trial termination
    |
    Yondelis (trabectedin)
    4d
    NeoSarc: Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (clinicaltrials.gov)
    P2, N=0, Withdrawn, Gustave Roussy, Cancer Campus, Grand Paris | N=36 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    4d
    Identification of a novel PRUNE2::NTRK2 gene fusion in soft tissue sarcoma patients-friend or foe? Case series. (PubMed, Ther Adv Med Oncol)
    Although NTRK-associated fusions are significant in various cancers and have led to the development of targeted therapies, such as larotrectinib and entrectinib, the specific molecular impact of atypical PRUNE2::NTRK2 fusion remains unclear. The PRUNE2::NTRK2 gene fusions described here express a non-functional TrkB protein, and it is unclear whether the PRUNE2 function is intact or affected.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
    4d
    Prognostic significance of biomarker expression on immunohistochemistry for overall survival in osteosarcoma: An overview of systematic reviews. (PubMed, J Clin Orthop Trauma)
    Overexpression of VEGF, HIF-1α, Ezrin, and p53 was strongly associated with increased mortality risk in osteosarcoma. These findings may guide patient counselling, biomarker panel optimization, and the development of targeted therapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • VEGFA (Vascular endothelial growth factor A) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • EZR (Ezrin)
    4d
    Primary Bone Sclerosing Epithelioid Fibrosarcoma: A Case Report and Literature Review. (PubMed, Cureus)
    Timely identification and precise diagnosis with specific immunohistochemistry are crucial in guiding an appropriate treatment strategy. Our analysis of 38 cases, including our case, showed a male predominance, spinal involvement, and a high MUC4 positivity rate, reinforcing its role as a key diagnostic marker.
    Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated)